» Articles » PMID: 33437350

COVID-19 Associated Thromboinflammation of Renal Capillary: Potential Mechanisms and Treatment

Overview
Journal Am J Transl Res
Specialty General Medicine
Date 2021 Jan 13
PMID 33437350
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Coronavirus disease 2019 (COVID-19) infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic disease with high morbidity and mortality. Inflammatory and thrombosis are its main manifestations. As an important organ of hemofiltration metabolism, the kidney is prone to blockage and destruction when filter high inflammatory and high viscous blood of COVID-19, resulting in the loss of a large amount of protein, aggravating blood concentration, and then worsening COVID-19 hypercoagulability, which may explain the phenomenon of erythrocytes aggregation blocking the capillary lumen and the main reason why the kidney has become the second largest involvement organs. Therefore, this review discusses the effects of pathophysiological mechanisms such as inflammatory storm, endothelial injury, phosphatidylserine expression, extracellular traps release on renal capillary thrombosis caused by COVID-19 infection. Meanwhile, in view of the above mechanisms, we put forward the potential targets of antithrombotic therapy, and graded management of patients, reasonable use of drugs according to the severity of the disease and the choice of time. And we support the view of prevention of thrombus before admission, continuous anticoagulation and drug choice after discharge. It is suggested that the symptomatic and supportive treatment of renal disease in critically ill patients should be combined with the concept of antithrombotic therapy. The ultimate goal is to reduce the occurrence and development of kidney disease, provide direction for the current management of COVID-19 with kidney disease, and reduce the mortality of COVID-19.

Citing Articles

The potential effect of iopamidol contrast on renal function in patients infected with SARS-CoV-2 virus: A retrospective cohort study.

Tersakyan S, Chappidi M, Patel A, Hainsworth K, Alshoubi A Int J Crit Illn Inj Sci. 2022; 12(3):155-159.

PMID: 36506924 PMC: 9728076. DOI: 10.4103/ijciis.ijciis_92_21.


Circulating Microparticles in the Pathogenesis and Early Anticoagulation of Thrombosis in COVID-19 With Kidney Injury.

Wang C, Yu C, Novakovic V, Xie R, Shi J Front Cell Dev Biol. 2022; 9:784505.

PMID: 35118071 PMC: 8804312. DOI: 10.3389/fcell.2021.784505.


The Central Role of Extracellular Vesicles in the Mechanisms of Thrombosis in COVID-19 Patients With Cancer and Therapeutic Strategies.

Jing H, Zuo N, Novakovic V, Shi J Front Cell Dev Biol. 2022; 9:792335.

PMID: 35096822 PMC: 8790316. DOI: 10.3389/fcell.2021.792335.


Acute kidney injury in moderate and severe COVID-19 patients: Report of two university hospitals.

Radulescu D, Tuta L, David C, Bogeanu C, Onofrei S, Stepan E Exp Ther Med. 2021; 23(1):37.

PMID: 34849152 PMC: 8613528. DOI: 10.3892/etm.2021.10959.


Neutrophil Extracellular Traps (NETs) in Severe SARS-CoV-2 Lung Disease.

Szturmowicz M, Demkow U Int J Mol Sci. 2021; 22(16).

PMID: 34445556 PMC: 8396177. DOI: 10.3390/ijms22168854.


References
1.
Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-OCallaghan A, Pardos-Gea J, Quintana A . Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 2020; 19(7):102569. PMC: 7252146. DOI: 10.1016/j.autrev.2020.102569. View

2.
South A, Brady T, Flynn J . ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective. Hypertension. 2020; 76(1):16-22. PMC: 7289676. DOI: 10.1161/HYPERTENSIONAHA.120.15291. View

3.
Blanc-Brude O, Archer F, Leoni P, Derian C, Bolsover S, Laurent G . Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation. Exp Cell Res. 2005; 304(1):16-27. DOI: 10.1016/j.yexcr.2004.10.021. View

4.
van Gorp E, Suharti C, ten Cate H, Dolmans W, van der Meer J, Ten Cate J . Review: infectious diseases and coagulation disorders. J Infect Dis. 1999; 180(1):176-86. DOI: 10.1086/314829. View

5.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View